Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Korro Bio Inc (KRRO)

Korro Bio Inc (KRRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 77,504
  • Shares Outstanding, K 9,417
  • Annual Sales, $ 2,270 K
  • Annual Income, $ -83,580 K
  • EBIT $ -97 M
  • EBITDA $ -95 M
  • 60-Month Beta 3.03
  • Price/Sales 32.76
  • Price/Cash Flow N/A
  • Price/Book 0.75

Options Overview Details

View History
  • Implied Volatility 94.70% (+24.14%)
  • Historical Volatility 459.47%
  • IV Percentile 13%
  • IV Rank 9.85%
  • IV High 315.74% on 11/12/25
  • IV Low 70.56% on 12/11/25
  • Expected Move (DTE 4) 0.82 (10.02%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 139
  • Volume Avg (30-Day) 802
  • Put/Call OI Ratio 8.79
  • Today's Open Interest 14,765
  • Open Int (30-Day) 6,442
  • Expected Range 7.41 to 9.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.86
  • Number of Estimates 5
  • High Estimate -1.44
  • Low Estimate -2.10
  • Prior Year -2.26
  • Growth Rate Est. (year over year) +17.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.20 +58.14%
on 12/02/25
8.83 -6.79%
on 12/12/25
-23.19 (-73.81%)
since 11/12/25
3-Month
5.20 +58.14%
on 12/02/25
55.89 -85.27%
on 10/16/25
-22.53 (-73.24%)
since 09/12/25
52-Week
5.20 +58.14%
on 12/02/25
55.89 -85.27%
on 10/16/25
-35.73 (-81.28%)
since 12/12/24

Most Recent Stories

More News
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients     — KRRO-110 did not reach projected...

KRRO : 8.23 (+4.18%)
Korro Bio CFO Vineet Agarwal Resigns, Interim Appointed

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Korro Bio...

KRRO : 8.23 (+4.18%)
Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio today and set a price target of $180.00. The company’s shares closed yesterday at $45.72.Elevate Your Investing Strategy: Take...

KRRO : 8.23 (+4.18%)
Korro to Participate in Upcoming Investor and Scientific Conferences

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific...

KRRO : 8.23 (+4.18%)
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

—  Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 —  Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple...

KRRO : 8.23 (+4.18%)
Korro to Participate in Upcoming Investor Conferences

KRRO : 8.23 (+4.18%)
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

KRRO : 8.23 (+4.18%)
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

KRRO : 8.23 (+4.18%)
Korro Reports Full Year 2024 Financial Results and Provides Business Updates

KRRO : 8.23 (+4.18%)
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

KRRO : 8.23 (+4.18%)

Business Summary

Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.

See More

Key Turning Points

3rd Resistance Point 9.82
2nd Resistance Point 9.33
1st Resistance Point 8.78
Last Price 8.23
1st Support Level 7.73
2nd Support Level 7.24
3rd Support Level 6.69

See More

52-Week High 55.89
Fibonacci 61.8% 36.53
Fibonacci 50% 30.55
Fibonacci 38.2% 24.57
Last Price 8.23
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar